[1]
|
S. B. Baylin and J. E. Ohm, “Epigenetic Gene Silencing in Cancer—A Mechanism for Early Oncogenic Pathway Addiction?” Nature Reviews Cancer, Vol. 6, No. 2, 2006, pp. 107-116. doi:10.1038/nrc1799
|
[2]
|
J. K. Choi and L. J. Howe, “Histone Acetylation: Truth of Consequences?” Biochemistry and Cell Biology, Vol. 87, No. 1, 2009, pp. 139-150. doi:10.1139/O08-112
|
[3]
|
J. E. Bolden, M. J. Peart and R. W. Johnstone, “Anticancer Activities of Histone Deacetylase Inhibitors,” Nature Reviews Drug Discovery, Vol. 5, No. 9, 2006, pp. 769-784. doi:10.1038/nrd2133
|
[4]
|
M. Duvic, R. Talpur, X. Ni, C. Zhang, P. Hazarika, C. Kelly, J. H. Chiao, J. F. Reilly, J. L. Ricker, V. M. Richon, et al., “Phase 2 Trial of Oral Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) for Refractory Cutaneous TCell Lymphoma (CTCL),” Blood, Vol. 109, No. 1, 2007, pp. 31-39. doi:10.1182/blood-2006-06-025999
|
[5]
|
P. Atadja, M. Hsu, P. Kwon, N. Trogani, K. Bhalla and S. Remiszewski, “Molecular and Cellular Basis for the AntiProliferative Effects of the HDAC Inhibitor LAQ824,” Novartis Foundation Symposium, Vol. 259, 2004, pp. 249-266, discussion 266-268, 285-288.
doi:10.1002/0470862637.ch19
|
[6]
|
P. A. Jones and S. B. Baylin, “The Epigenomics of Cancer,” Cell, Vol. 128, No. 4, 2007, pp. 683-692.
doi:10.1016/j.cell.2007.01.029
|
[7]
|
W. Lutz, J. Leon and M. Eilers, “Contributions of Myc to Tumorigenesis,” Biochimica et Biophysica Acta, Vol. 1602, No. 1, 2002, pp. 61-71.
|
[8]
|
S. Pelengaris, M. Khan and G. Evan, “c-MYC: More than Just a Matter of Life and Death,” Nature Reviews Cancer, Vol. 2, No. 10, 2002, pp. 764-776. doi:10.1038/nrc904
|
[9]
|
H. A. Armelin, M. C. Armelin, K. Kelly, T. Stewart, P. Leder, B. H. Cochran and C. D. Stiles, “Functional Role for c-Myc in Mitogenic Response to Platelet-Derived Growth Factor,” Nature, Vol. 310, No. 5979, 1984, pp. 655-660. doi:10.1038/310655a0
|
[10]
|
S. O. Freytag, “Enforced Expression of the c-Myc Oncogene Inhibits Cell Differentiation by Precluding Entry into a Distinct Predifferentiation State in G0/G1,” Molecular and Cellular Biology, Vol. 8, No. 4, 1988, pp. 1614-1624.
|
[11]
|
G. I. Evan, A. H. Wyllie, C. S. Gilbert, T. D. Littlewood, H. Land, M. Brooks, C. M. Waters, L. Z. Penn and D. C. Hancock, “Induction of Apoptosis in Fibroblasts by cMyc Protein,” Cell, Vol. 69, No. 1, 1992, pp. 119-128.
doi:10.1016/0092-8674(92)90123-T
|
[12]
|
M. H. Jamerson, M. D. Johnson and R. B. Dickson, “Of Mice and Myc: c-Myc and Mammary Tumorigenesis,” Journal of Mammary Gland Biology and Neoplasia, Vol. 9, No. 1, 2004, pp. 27-37.
doi:10.1023/B:JOMG.0000023586.69263.0b
|
[13]
|
R. Visone and C. M. Croce, “MiRNAs and Cancer,” American Journal of Pathology, Vol. 174, No. 4, 2009, pp. 1131-1138. doi:10.2353/ajpath.2009.080794
|
[14]
|
W. C. Cho, “OncomiRs: The Discovery and Progress of microRNAs in Cancers,” Molecular Cancer, Vol. 6, 2007, 60. doi:10.1186/1476-4598-6-60
|
[15]
|
Y. Hayashita, H. Osada, Y. Tatematsu, H. Yamada, K. Yanagisawa, S. Tomida, Y. Yatabe, K. Kawahara, Y. Sekido and T. Takahashi, “A Polycistronic microRNA Cluster, miR-17-92, Is Overexpressed in Human Lung Cancers and Enhances Cell Proliferation,” Cancer Research, Vol. 65, No. 21, 2005, pp. 9628-9632.
doi:10.1158/0008-5472.CAN-05-2352
|
[16]
|
L. He, J. M. Thomson, M. T. Hemann, E. HernandoMonge, D. Mu, S. Goodson, S. Powers, C. Cordon-Cardo, S. W. Lowe, G. J. Hannon, et al., “A Microrna Polycistron As a Potential Human Oncogene,” Nature, Vol. 435, No. 7043, 2005, pp. 828-833. doi:10.1038/nature03552
|
[17]
|
A. Ventura, A. G. Young, M. M. Winslow, L. Lintault, A. Meissner, S. J. Erkeland, J. Newman, R. T. Bronson, D. Crowley, J. R. Stone, et al., “Targeted Deletion Reveals Essential and Overlapping Functions of the miR-17 through 92 Family of miRNA Clusters,” Cell, Vol. 132, No. 5, 2008, pp. 875-886. doi:10.1016/j.cell.2008.02.019
|
[18]
|
V. Olive, I. Jiang and L. He, “mir-17-92, a Cluster of miRNAs in the Midst of the Cancer Network,” International Journal of Biochemistry & Cell Biology, Vol. 42, No. 8, 2009, pp. 1348-1354.
doi:10.1016/j.biocel.2010.03.004
|
[19]
|
L. Hong, M. Lai, M. Chen, C. Xie, R. Liao, Y. J. Kang, C. Xiao, W. Y. Hu, J. Han and P. Sun, “The miR-17-92 Cluster of microRNAs Confers Tumorigenicity by Inhibiting Oncogene-Induced Senescence,” Cancer Research, Vol. 70, No. 21, pp. 8547-8557.
doi:10.1158/0008-5472.CAN-10-1938
|
[20]
|
M. Dews, A. Homayouni, D. Yu, D. Murphy, C. Sevignani, E. Wentzel, E. E. Furth, W. M. Lee, G. H. Enders, J. T. Mendell, et al., “Augmentation of Tumor Angiogenesis by a Myc-Activated microRNA Cluster,” Nature Genetics, Vol. 38, No. 9, 2006, pp. 1060-1065. doi:10.1038/ng1855
|
[21]
|
A. Ota, H. Tagawa, S. Karnan, S. Tsuzuki, A. Karpas, S. Kira, Y. Yoshida and M. Seto, “Identification and Characterization of a Novel Gene, C13orf25, as a Target for 13q31-q32 Amplification in Malignant Lymphoma,” Cancer Research, Vol. 64, No. 9, 2004, pp. 3087-3095.
doi:10.1158/0008-5472.CAN-03-3773
|
[22]
|
K. A. O’Donnell, E. A. Wentzel, K. I. Zeller, C. V. Dang and J. T. Mendell, “c-Myc-Regulated microRNAs Modulate E2F1 Expression,” Nature, Vol. 435, No. 7043, 2005, pp. 839-843. doi:10.1038/nature03677
|
[23]
|
Y. Sylvestre, V. De Guire, E. Querido, U. K. Mukhopadhyay, V. Bourdeau, F. Major, G. Ferbeyre and P. Chartrand, “An E2F/miR-20a Autoregulatory Feedback Loop,” Journal of Biological Chemistry, Vol. 282, No. 4, 2007, pp. 2135-2143. doi:10.1074/jbc.M608939200
|
[24]
|
P. Mu, Y. C. Han, D. Betel, E. Yao, M. Squatrito, P. Ogrodowski, E. de Stanchina, A. D’Andrea, C. Sander and A. Ventura, “Genetic Dissection of the miR-17~92 Cluster of microRNAs in Myc-Induced B-Cell Lymphomas,” Genes & Development, Vol. 23, No. 24, 2009, pp. 2806-2811. doi:10.1101/gad.1872909
|
[25]
|
L. Fontana, M. E. Fiori, S. Albini, L. Cifaldi, S. Giovinazzi, M. Forloni, R. Boldrini, A. Donfrancesco, V. Federici, P. Giacomini, et al., “Antagomir-17-5p Abolishes the Growth of Therapy-Resistant Neuroblastoma through p21 and BIM,” PLoS One, Vol. 3, No. 5, 2008, p. e2236. doi:10.1371/journal.pone.0002236
|
[26]
|
C. Xiao, L. Srinivasan, D. P. Calado, H. C. Patterson, B. Zhang, J. Wang, J. M. Henderson, J. L. Kutok and K. Rajewsky, “Lymphoproliferative Disease and Autoimmunity in Mice with Increased miR-17-92 Expression in Lymphocytes,” Nature Immunology, Vol. 9, No. 4, 2008, pp. 405-414. doi:10.1038/ni1575
|
[27]
|
S. Fotheringham, M. T. Epping, L. Stimson, O. Khan, V. Wood, F. Pezzella, R. Bernards and N. B. La Thangue, “Genome-Wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis,” Cancer Cell, Vol. 15, No. 1, 2009, pp. 57-66. doi:10.1016/j.ccr.2008.12.001
|
[28]
|
S. K. Seo, H. O. Jin, S. H. Woo, Y. S. Kim, S. An, J. H. Lee, S. I. Hong, K. H. Lee, T. B. Choe and I. C. Park, “Histone Deacetylase Inhibitors Sensitize Human NonSmall Cell Lung Cancer Cells to Ionizing Radiation through Acetyl p53-Mediated c-myc Down-Regulation,” Journal of Thoracic Oncology, Vol. 6, No. 8, pp. 1313-1319. doi:10.1097/JTO.0b013e318220caff
|
[29]
|
X. Jiang, Y. H. Tsang and Q. Yu, “c-Myc Overexpression sensitizes Bim-Mediated Bax Activation for Apoptosis Induced by Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) through Regulating Bcl-2/ Bcl-xL Expression,” International Journal of Biochemistry & Cell Biology, Vol. 39, No. 5, 2007, pp. 1016-1025.
doi:10.1016/j.biocel.2007.01.024
|
[30]
|
B. Brodska, P. Otevrelova and I. Kalousek, “Variations in c-Myc and p21WAF1 Expression Protect Normal Peripheral Blood Lymphocytes against BimEL-Mediated Cell Death,” Cell Biochemistry & Function, Vol. 27, No. 3, 2009, pp. 167-175. doi:10.1002/cbf.1552
|
[31]
|
S. K. Oster, D. Y. Mao, J. Kennedy and L. Z. Penn, “Functional Analysis of the N-Terminal Domain of the Myc Oncoprotein,” Oncogene, Vol. 22, No. 13, 2003, pp. 1998-2010. doi:10.1038/sj.onc.1206228
|
[32]
|
L. Kretzner, A. Scuto, P. M. Dino, C. M. Kowolik, J. Wu, P. Ventura, R. Jove, S. J. Forman, Y. Yen and M. H. Kirschbaum, “Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels,” Cancer Research, Vol. 71, No. 11, 2011, pp. 3912-3920.
doi:10.1158/0008-5472.CAN-10-2259
|
[33]
|
K. J. Humphreys, L. Cobiac, R. K. Le Leu, M. B. Van der Hoek and M. Z. Michael, “Histone Deacetylase Inhibition in Colorectal Cancer Cells Reveals Competing Roles for Members of the Oncogenic miR-17-92 Cluster,” Molecular Carcinogenesis, Vol. 52, No. 6, 2013, pp. 459-474.
doi:10.1002/mc.21879
|
[34]
|
W. S. el-Deiry, J. W. Harper, P. M. O’Connor, V. E. Velculescu, C. E. Canman, J. Jackman, J. A. Pietenpol, M. Burrell, D. E. Hill, Y. Wang, et al., “WAF1/CIP1 Is Induced in p53-mediated G1 Arrest and Apoptosis,” Cancer Research, Vol. 54, No. 5, 1994, pp. 1169-1174.
|
[35]
|
L. O’Connor, A. Strasser, L. A. O’Reilly, G. Hausmann, J. M. Adams, S. Cory and D. C. Huang, “Bim: A Novel Member of the Bcl-2 Family that Promotes Apoptosis,” EMBO Journal, Vol. 17, No. 2, 1998, pp. 384-395.
doi:10.1093/emboj/17.2.384
|
[36]
|
F. Petrocca, A. Vecchione and C. M. Croce, “Emerging Role of miR-106b-25/miR-17-92 Clusters in the Control of Transforming Growth Factor Beta Signaling,” Cancer Research, Vol. 68, No. 20, 2008, pp. 8191-8194.
doi:10.1158/0008-5472.CAN-08-1768
|
[37]
|
M. D. Erisman, P. G. Rothberg, R. E. Diehl, C. C. Morse, J. M. Spandorfer and S. M. Astrin, “Deregulation of c-Myc Gene Expression in Human Colon Carcinoma Is Not Accompanied by Amplification or Rearrangement of the Gene,” Molecular and Cellular Biology, Vol. 5, No. 8, 1985, pp. 1969-1976.
|
[38]
|
A. C. Faber, D. Li, Y. Song, M. C. Liang, B. Y. Yeap, R. T. Bronson, E. Lifshits, Z. Chen, S. M. Maira, C. Garcia-Echeverria, et al., “Differential Induction of Apoptosis in HER2 and EGFR Addicted Cancers Following PI3K Inhibition,” Proceedings of the National Academy of Sciences USA, Vol. 106, No. 46, 2009, pp. 19503-19508. doi:10.1073/pnas.0905056106
|
[39]
|
M. Gorospe, C. Cirielli, X. Wang, P. Seth, M. C. Capogrossi and N. J. Holbrook, “p21(Waf1/Cip1) Protects against p53-Mediated Apoptosis of Human Melanoma Cells,” Oncogene, Vol. 14, No. 8, 1997, pp. 929-935.
doi:10.1038/sj.onc.1200897
|
[40]
|
F. Bunz, A. Dutriaux, C. Lengauer, T. Waldman, S. Zhou, J. P. Brown, J. M. Sedivy, K. W. Kinzler and B. Vogelstein, “Requirement for p53 and p21 to Sustain G2 Arrest after DNA Damage,” Science, Vol. 282, No. 5393, 1998, pp. 1497-1501. doi:10.1126/science.282.5393.1497
|
[41]
|
T. Waldman, C. Lengauer, K. W. Kinzler and B. Vogelstein, “Uncoupling of S Phase and Mitosis Induced by Anticancer Agents in Cells Lacking p21,” Nature, Vol. 381, No. 6584, 1996, pp. 713-716. doi:10.1038/381713a0
|
[42]
|
X. Ma, H. H. Ezzeldin and R. B. Diasio, “Histone Deacetylase Inhibitors: Current Status and Overview of Recent Clinical Trials,” Drugs, Vol. 69, No. 14, 2009, pp. 1911-1934. doi:10.2165/11315680-000000000-00000
|